Tenaya Therapeutics Announces Research Leadership Updates

Core Insights - Tenaya Therapeutics, a clinical-stage biotechnology company, announced leadership changes in its research team, including the promotion of Kathy Ivey, Ph.D., to Senior Vice President of Research and the transition of Timothy Hoey, Ph.D., to an advisory role [2][10] - Barry J. Byrne, M.D., Ph.D., a pediatric cardiologist and genetic therapy expert, has joined Tenaya's Scientific Advisory Board, bringing valuable expertise in genetic therapies for heart diseases [9][12] Leadership Changes - Kathy Ivey has been with Tenaya since its formation in 2016 and has led the company's genetic medicines discovery efforts, overseeing programs in gene therapy, gene editing, and regenerative medicine [3][11] - Timothy Hoey, who served as Chief Scientific Officer since 2017, will remain with the company in an advisory capacity after stepping down from his role [2][10] - Jin-Long Chen, Ph.D., is stepping down from the Board of Directors after over seven years of service to focus on other commitments [4][10] Company Mission and Pipeline - Tenaya Therapeutics aims to discover, develop, and deliver potentially curative therapies targeting the underlying causes of heart disease [13] - The company is advancing a pipeline that includes TN-201 for MYBPC3-associated hypertrophic cardiomyopathy, TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, and TN-301, a small molecule HDAC6 inhibitor for heart failure with preserved ejection fraction [13]